CSL Limited

ASX CSL.AX

CSL Limited Capital Expenditure for the year ending June 30, 2024: USD -1.26 B

CSL Limited Capital Expenditure is USD -1.26 B for the year ending June 30, 2024, a 49.99% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

CSL Limited Capital Expenditure for the year ending June 30, 2023 was USD -2.52 B, a -46.20% change year over year.
CSL Limited Capital Expenditure for the year ending June 30, 2022 was USD -1.72 B, a -2.54% change year over year.
CSL Limited Capital Expenditure for the year ending June 30, 2021 was USD -1.68 B, a -18.70% change year over year.
CSL Limited Capital Expenditure for the year ending June 30, 2020 was USD -1.41 B, a -12.56% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

ASX: CSL.AX

CSL Limited

CEO	Dr. Paul F. McKenzie Ph.D.
IPO Date	June 1, 1994
Location	Australia
Headquarters	45 Poplar Road
Employees	32,698
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Key trends

Past 5 years